NY-ESO-1 expression in sarcomas a diagnostic marker and immunotherapy target

Jin Ping Lai, Avi Z. Rosenberg, Markku M. Miettinen, Chyi Chia R. Lee

Research output: Contribution to journalComment/debatepeer-review

Abstract

NY-ES O-1 (CTAG 1B) is highly expressed in the majority of synovial sarcomas and myxoid/round cell liposarcomas as well as in a subset of melanomas, but only rarely in other mesenchymal tumors. This points to a potential for using NY-ES O-1 in the differential diagnosis of these lesions. Furthermore, promising results have been obtained in clinical trials testing NY-ES O-1-targeted immunotherapy in subsets of melanoma and synovial sarcoma patients.

Original languageEnglish (US)
Pages (from-to)1409-1410
Number of pages2
JournalOncoImmunology
Volume1
Issue number8
DOIs
StatePublished - 2012
Externally publishedYes

Keywords

  • Cancer-testis antigen
  • Clinical trial
  • Diagnostic marker
  • Immunotherapy
  • Melanoma
  • NY-ESO-1
  • Sarcomas
  • Synovial sarcoma
  • T-cell receptor
  • Therapeutic target

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint

Dive into the research topics of 'NY-ESO-1 expression in sarcomas a diagnostic marker and immunotherapy target'. Together they form a unique fingerprint.

Cite this